Compare Stocks: ATXS, NRIX, BEAM, and RARE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXS Astria Therapeutics	$12.58 +0.6%	$12.68	$3.69 ▼ $13.29	$718.13M	0.01	1.01 million shs	3.20 million shs
BEAM Beam Therapeutics	$29.07 +9.4%	$30.12	$15.60 ▼ $38.26	$2.74B	2.23	1.63 million shs	3.10 million shs
NRIX Nurix Therapeutics	$27.79 +3.2%	$23.04	$8.19 ▼ $28.23	$2.79B	1.79	1.03 million shs	2.10 million shs
RARE Ultragenyx Pharmaceutical	$26.24 +2.9%	$28.52	$18.29 ▼ $39.89	$2.51B	0.35	1.95 million shs	2.70 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXS Astria Therapeutics	0.00%	0.00%	0.00%	0.00%	+99.68%
BEAM Beam Therapeutics	+9.41%	+8.84%	+10.41%	+5.06%	+77.80%
NRIX Nurix Therapeutics	+3.19%	+4.36%	+22.37%	+58.53%	+182.42%
RARE Ultragenyx Pharmaceutical	+2.94%	-2.31%	-8.03%	+10.67%	-9.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATXS Astria Therapeutics	$12.58 +0.6%	$12.68	$3.69 ▼ $13.29	$718.13M	0.01	1.01 million shs	3.20 million shs
BEAM Beam Therapeutics	$29.07 +9.4%	$30.12	$15.60 ▼ $38.26	$2.74B	2.23	1.63 million shs	3.10 million shs
NRIX Nurix Therapeutics	$27.79 +3.2%	$23.04	$8.19 ▼ $28.23	$2.79B	1.79	1.03 million shs	2.10 million shs
RARE Ultragenyx Pharmaceutical	$26.24 +2.9%	$28.52	$18.29 ▼ $39.89	$2.51B	0.35	1.95 million shs	2.70 million shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATXS Astria Therapeutics	0.00%	0.00%	0.00%	0.00%	+99.68%
BEAM Beam Therapeutics	+9.41%	+8.84%	+10.41%	+5.06%	+77.80%
NRIX Nurix Therapeutics	+3.19%	+4.36%	+22.37%	+58.53%	+182.42%
RARE Ultragenyx Pharmaceutical	+2.94%	-2.31%	-8.03%	+10.67%	-9.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATXS Astria Therapeutics	2.00	Hold	$24.20	92.37% Upside
BEAM Beam Therapeutics	2.69	Moderate Buy	$49.00	68.56% Upside
NRIX Nurix Therapeutics	2.80	Moderate Buy	$34.21	23.12% Upside
RARE Ultragenyx Pharmaceutical	2.83	Moderate Buy	$57.82	120.36% Upside

Current Analyst Ratings Breakdown

Latest ATXS, NRIX, BEAM, and RARE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/10/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/10/2026	NRIX Nurix Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$33.00 ➝ $36.00
8/10/2026	RARE Ultragenyx Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
8/5/2026	RARE Ultragenyx Pharmaceutical	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$47.00 ➝ $45.00
8/4/2026	NRIX Nurix Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$34.00
8/4/2026	RARE Ultragenyx Pharmaceutical	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$43.00 ➝ $35.00
7/28/2026	NRIX Nurix Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$36.00 ➝ $38.00
7/22/2026	NRIX Nurix Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$23.00 ➝ $31.00
7/17/2026	BEAM Beam Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	NRIX Nurix Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	NRIX Nurix Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$30.00 ➝ $34.00

(Data available from 8/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATXS Astria Therapeutics	$706K	1,017.18	N/A	N/A	$3.97 per share	3.17
BEAM Beam Therapeutics	$139.74M	21.49	N/A	N/A	$10.34 per share	2.81
NRIX Nurix Therapeutics	$83.98M	34.34	N/A	N/A	$5.29 per share	5.25
RARE Ultragenyx Pharmaceutical	$673M	3.84	N/A	N/A	($2.95) per share	-8.89

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATXS Astria Therapeutics	-$94.26M	-$2.14	N/A	N/A	N/A	N/A	-68.81%	-41.12%	N/A
BEAM Beam Therapeutics	-$79.99M	-$0.86	N/A	N/A	N/A	-54.75%	-30.71%	-24.07%	11/3/2026 (Estimated)
NRIX Nurix Therapeutics	-$264.46M	-$3.45	N/A	N/A	N/A	-928.44%	-76.09%	-57.31%	10/8/2026 (Estimated)
RARE Ultragenyx Pharmaceutical	-$575M	-$5.84	N/A	N/A	N/A	-81.79%	-1,024.42%	-44.40%	11/3/2026 (Estimated)

Latest ATXS, NRIX, BEAM, and RARE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2026	Q2 2026	BEAM Beam Therapeutics	-$1.11	-$1.18	-$0.07	-$1.18	$16.37 million	$0.49 million
8/4/2026	Q2 2026	RARE Ultragenyx Pharmaceutical	-$1.22	-$0.90	+$0.32	-$0.90	$183.08 million	$214.00 million
7/9/2026	Q2 2026	NRIX Nurix Therapeutics	-$0.73	-$0.81	-$0.08	-$0.81	$15.29 million	$9.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
NRIX Nurix Therapeutics	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATXS Astria Therapeutics	N/A	10.78	10.78
BEAM Beam Therapeutics	0.09	14.57	14.57
NRIX Nurix Therapeutics	N/A	6.34	6.34
RARE Ultragenyx Pharmaceutical	N/A	1.73	1.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATXS Astria Therapeutics	98.98%
BEAM Beam Therapeutics	99.68%
NRIX Nurix Therapeutics	N/A
RARE Ultragenyx Pharmaceutical	97.67%

Insider Ownership

Company	Insider Ownership
ATXS Astria Therapeutics	4.50%
BEAM Beam Therapeutics	3.80%
NRIX Nurix Therapeutics	6.70%
RARE Ultragenyx Pharmaceutical	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATXS Astria Therapeutics	30	57.09 million	54.52 million	Optionable
BEAM Beam Therapeutics	510	103.29 million	99.36 million	Optionable
NRIX Nurix Therapeutics	300	103.78 million	96.83 million	Optionable
RARE Ultragenyx Pharmaceutical	1,371	98.59 million	93.46 million	Optionable

ATXS, NRIX, BEAM, and RARE Headlines

Recent News About These Companies

Ultragenyx's gene therapy for rare metabolic disorder secures US FDA nod

August 19 at 5:33 PM | reuters.com

Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)

August 19 at 5:21 PM | globenewswire.com

Bank of America Corp DE Has $21.93 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RARE

August 19 at 3:04 AM | marketbeat.com

Rare stock clocks two consecutive days of losses ahead of weekend FDA decision on gene therapy

August 19 at 1:36 AM | msn.com

Ultragenyx: Undervalued Ahead Of Two FDA Decisions

August 14, 2026 | seekingalpha.com

HC Wainwright Issues Optimistic Outlook for RARE Earnings

August 14, 2026 | americanbankingnews.com

Assenagon Asset Management S.A. Sells 2,136,807 Shares of Ultragenyx Pharmaceutical Inc. $RARE

August 13, 2026 | marketbeat.com

HC Wainwright Has Bullish Estimate for RARE Q3 Earnings

August 12, 2026 | marketbeat.com

Brokerages Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Price Target at $57.82

August 12, 2026 | americanbankingnews.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Earns "Buy" Rating from HC Wainwright

August 12, 2026 | americanbankingnews.com

Ultragenyx and Baylor Research Institute Settle DOJOLVI Generic Patent Lawsuit with Esjay Pharma

August 11, 2026 | kalkinemedia.comK

Mereo BioPharma and Sentynl Enter Option and License Agreement for Alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease

August 11, 2026 | quiverquant.comQ

Is Q2 Revenue Growth And Narrower Loss Altering The Investment Case For Ultragenyx Pharmaceutical (RARE)?

August 10, 2026 | finance.yahoo.com

Ultragenyx Pharmaceutical's (RARE) Buy Rating Reiterated at HC Wainwright

August 10, 2026 | marketbeat.com

Sei Investments Co. Sells 61,632 Shares of Ultragenyx Pharmaceutical Inc. $RARE

August 10, 2026 | marketbeat.com

Barclays Sticks to Its Buy Rating for Ultragenyx Pharmaceutical (RARE)

August 9, 2026 | theglobeandmail.com

Quantinno Capital Management LP Purchases 137,758 Shares of Ultragenyx Pharmaceutical Inc. $RARE

August 8, 2026 | marketbeat.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Rating Upgraded by Wall Street Zen

August 8, 2026 | marketbeat.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by Analysts

August 7, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Ultragenyx Pharmaceutical (RARE) and Beam Therapeutics (BEAM)

August 6, 2026 | theglobeandmail.com

Ultragenyx Pharmaceutical Q2 Loss Narrows as Revenue Rises; 2026 Revenue Guidance Reaffirmed

August 6, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXS, NRIX, BEAM, and RARE Company Descriptions

Astria Therapeutics NASDAQ:ATXS

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Beam Therapeutics NASDAQ:BEAM

$29.07 +2.50 (+9.41%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$29.08 +0.02 (+0.05%)

As of 08/19/2026 07:57 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Nurix Therapeutics NASDAQ:NRIX

$27.79 +0.86 (+3.19%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$27.98 +0.19 (+0.68%)

As of 08/19/2026 07:52 PM Eastern

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Ultragenyx Pharmaceutical NASDAQ:RARE

$26.24 +0.75 (+2.94%)

Closing price 08/19/2026 04:00 PM Eastern

Extended Trading

$28.14 +1.90 (+7.25%)

As of 08/19/2026 08:00 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATXS, NRIX, BEAM, and RARE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATXS, NRIX, BEAM, and RARE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATXS, NRIX, BEAM, and RARE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXS, NRIX, BEAM, and RARE Company Descriptions

Astria Therapeutics NASDAQ:ATXS

Beam Therapeutics NASDAQ:BEAM

Nurix Therapeutics NASDAQ:NRIX

Ultragenyx Pharmaceutical NASDAQ:RARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ATXS, NRIX, BEAM, and RARE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ATXS, NRIX, BEAM, and RARE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ATXS, NRIX, BEAM, and RARE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXS, NRIX, BEAM, and RARE Company Descriptions

Astria Therapeutics NASDAQ:ATXS

Beam Therapeutics NASDAQ:BEAM

Nurix Therapeutics NASDAQ:NRIX

Ultragenyx Pharmaceutical NASDAQ:RARE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools